Heart failure drug less effective in real world

November 27, 2012, Duke University Medical Center

A large study addressing the effectiveness and safety of aldosterone antagonist therapy for older heart failure patients has found notable differences between the drug's results in clinical trial vs. what occurs in actual practice, according to researchers at Duke Medicine.

Those differences have been noted anecdotally by doctors, and likely contributed to the slow adoption of aldosterone antagonists in clinical practice, but they had not been confirmed in a large study examining the drugs in real-world situations.

The Duke-led research, published Nov. 28, 2012, in the , suggests that doctors should more closely model the types of patients and the procedures followed in when prescribing drugs in practice.

"Understanding whether real-world effectiveness matches the efficacy of clinical trials is important to assure that we are implementing and providing the best care possible," said lead author Adrian F. Hernandez, M.D., MHS, a cardiologist and member of the Duke Clinical Research Institute. "We are in an era where drugs can be efficacious, and the question is can they be effective and safe in clinical practice as they're being used. That's where we find differences and need more studies."

Key efficacy trials decades ago reported impressive benefits of aldosterone antagonist therapy, but doctors have long had questions about its safety for older and sicker patients who may be at risk for retaining high levels of potassium in their blood – a potentially fatal condition known as .

Hernandez and colleagues used to identify older patients who had been hospitalized for heart failure or weak pumping action called reduced . Among more than 5,880 eligible patients, 1,070 were discharged with prescriptions for aldosterone antagonist drugs, which inhibit sodium reabsorption in the kidneys to lower fluid retention and, as a result, improve .

The research team found fewer benefits associated with the drugs than had originally been reported. There was no difference in deaths or hospital readmissions for cardiovascular events between the patients who went on the aldosterone antagonists and patients who did not. Patients taking the drugs were, however, less likely to be readmitted to the hospital for . At the same time, they were at significantly higher risk of readmission for hyperkalemia.

The study suggests that aldosterone antagonists might have limited success in reducing deaths among older patients. Potential reasons include a lack of adherence to therapy, and improper dosing and monitoring in practical use.

"Patient populations, monitoring, and procedures in clinical trials are different than in normal practice," Hernandez said. "High-risk , women and members of minority groups are typically underrepresented in clinical trials, while clinical trial participants tend to adhere to therapy and follow-up tests."

Hernandez said the study's findings highlight the importance of conducting clinical trials that can be easily generalized to real-world practice. At the same time, better protocols for aldosterone antagonist therapy could be established for doctors to ensure appropriate patient selection, correct dosing, medication adherence and early follow-up visits to screen for hyperkalemia.

"We can't have a paradigm where we give a pill and say come back in three months," Hernandez said. "Developing systems that encourage optimal use and monitoring of aldosterone antagonist therapy may help ensure that the effectiveness of this therapy in clinical practice approaches what was achieved in clinical trials."

Explore further: New data from studies bolsters case for using aldosterone antagonists in heart failure

Related Stories

New data from studies bolsters case for using aldosterone antagonists in heart failure

September 19, 2011
Roughly 5 million people in the United States live with heart failure, a condition in which the heart is unable to pump blood around the body effectively. The causes and types of heart failure vary greatly, and treatment ...

Tens of thousands of lives could potentially be saved by key heart failure therapies

June 6, 2011
A national study has found that nearly 68,000 deaths potentially could be prevented each year by optimally implementing key national guideline–recommended therapies, including critical medications and cardiac devices, ...

Combined use of recommended heart failure therapies significantly boosts survival odds

February 22, 2012
(Medical Xpress) -- A UCLA-led study has found that a combination of several key guideline-recommended therapies for heart failure treatment resulted in an improvment of up to 90 percent in the odds of survival over two years.

Recommended for you

Starting periods before age of 12 linked to heightened risk of heart disease and stroke

January 15, 2018
Starting periods early—before the age of 12—is linked to a heightened risk of heart disease and stroke in later life, suggests an analysis of data from the UK Biobank study, published online in the journal Heart.

'Decorated' stem cells could offer targeted heart repair

January 10, 2018
Although cardiac stem cell therapy is a promising treatment for heart attack patients, directing the cells to the site of an injury - and getting them to stay there - remains challenging. In a new pilot study using an animal ...

Exercise is good for the heart, high blood pressure is bad—researchers find out why

January 10, 2018
When the heart is put under stress during exercise, it is considered healthy. Yet stress due to high blood pressure is bad for the heart. Why? And is this always the case? Researchers of the German Centre for Cardiovascular ...

Two simple tests could help to pinpoint cause of stroke

January 10, 2018
Detecting the cause of the deadliest form of stroke could be improved by a simple blood test added alongside a routine brain scan, research suggests.

Heart-muscle patches made with human cells improve heart attack recovery

January 10, 2018
Large, human cardiac-muscle patches created in the lab have been tested, for the first time, on large animals in a heart attack model. This clinically relevant approach showed that the patches significantly improved recovery ...

Place of residence linked to heart failure risk

January 9, 2018
Location. Location. Location.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.